These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 29364918

  • 1. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.
    Chamorro V, Morales-Cano D, Milara J, Barreira B, Moreno L, Callejo M, Mondejar-Parreño G, Esquivel-Ruiz S, Cortijo J, Cogolludo Á, Barberá JA, Perez-Vizcaino F.
    PLoS One; 2018; 13(1):e0191239. PubMed ID: 29364918
    [Abstract] [Full Text] [Related]

  • 2. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K, Sydykov A, Tian X, Mamazhakypov A, Neupane B, Luitel H, Weissmann N, Seeger W, Grimminger F, Kretschmer A, Stasch JP, Ghofrani HA, Schermuly RT.
    Int J Cardiol; 2016 Aug 01; 216():85-91. PubMed ID: 27140341
    [Abstract] [Full Text] [Related]

  • 3. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
    Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, Kretschmer A, Stasch JP, Seeger W, Ghofrani HA, Schermuly RT.
    PLoS One; 2012 Aug 01; 7(8):e43433. PubMed ID: 22912874
    [Abstract] [Full Text] [Related]

  • 4. BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.
    Thorsen LB, Eskildsen-Helmond Y, Zibrandtsen H, Stasch JP, Simonsen U, Laursen BE.
    Eur J Pharmacol; 2010 Nov 25; 647(1-3):147-54. PubMed ID: 20828552
    [Abstract] [Full Text] [Related]

  • 5. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA.
    Respir Med; 2017 Jan 25; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [Abstract] [Full Text] [Related]

  • 6. Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs.
    Næsheim T, How OJ, Myrmel T.
    J Cardiovasc Pharmacol Ther; 2021 Jan 25; 26(1):75-87. PubMed ID: 32662299
    [Abstract] [Full Text] [Related]

  • 7. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
    Potoka KP, Wood KC, Baust JJ, Bueno M, Hahn SA, Vanderpool RR, Bachman T, Mallampalli GM, Osei-Hwedieh DO, Schrott V, Sun B, Bullock GC, Becker-Pelster EM, Wittwer M, Stampfuss J, Mathar I, Stasch JP, Truebel H, Sandner P, Mora AL, Straub AC, Gladwin MT.
    Am J Respir Cell Mol Biol; 2018 May 25; 58(5):636-647. PubMed ID: 29268036
    [Abstract] [Full Text] [Related]

  • 8. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
    Dees C, Beyer C, Distler A, Soare A, Zhang Y, Palumbo-Zerr K, Distler O, Schett G, Sandner P, Distler JH.
    Ann Rheum Dis; 2015 Aug 25; 74(8):1621-5. PubMed ID: 25817717
    [Abstract] [Full Text] [Related]

  • 9. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
    Goulopoulou S, Hannan JL, Matsumoto T, Ogbi S, Ergul A, Webb RC.
    Am J Physiol Heart Circ Physiol; 2015 Jul 15; 309(2):H297-304. PubMed ID: 25957216
    [Abstract] [Full Text] [Related]

  • 10. A focus on riociguat in the treatment of pulmonary arterial hypertension.
    Toxvig AK, Wehland M, Grimm D, Infanger M, Krüger M.
    Basic Clin Pharmacol Toxicol; 2019 Sep 15; 125(3):202-214. PubMed ID: 31206240
    [Abstract] [Full Text] [Related]

  • 11. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.
    Rai N, Veeroju S, Schymura Y, Janssen W, Wietelmann A, Kojonazarov B, Weissmann N, Stasch JP, Ghofrani HA, Seeger W, Schermuly RT, Novoyatleva T.
    Biomed Res Int; 2018 Sep 15; 2018():3293584. PubMed ID: 29511676
    [Abstract] [Full Text] [Related]

  • 12. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study.
    Milara J, Escrivá J, Ortiz JL, Juan G, Artigues E, Morcillo E, Cortijo J.
    Eur Respir J; 2016 Jun 15; 47(6):1737-49. PubMed ID: 27009174
    [Abstract] [Full Text] [Related]

  • 13. Inducible cyclooxygenase expression mediating hypoxia/reoxygenation-induced pulmonary vasoconstriction is attenuated by a cyclooxygenase inhibitor in rats.
    Su CL, Yuan DW, Chiang LL, Lee HL, Chen KH, Wang D.
    Transplant Proc; 2012 May 15; 44(4):929-32. PubMed ID: 22564588
    [Abstract] [Full Text] [Related]

  • 14. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
    Sandner P, Becker-Pelster EM, Stasch JP.
    Nitric Oxide; 2018 Jul 01; 77():88-95. PubMed ID: 29738821
    [Abstract] [Full Text] [Related]

  • 15. Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs.
    Weissmann N, Voswinckel R, Tadic A, Hardebusch T, Ghofrani HA, Schermuly RT, Seeger W, Grimminger F.
    Am J Respir Cell Mol Biol; 2000 Aug 01; 23(2):222-7. PubMed ID: 10919989
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM, Turrentine MW, Sheridan BC, Wang M, Fiore AC, Brown JW, Meldrum DR.
    Ann Thorac Surg; 2006 Jan 01; 81(1):272-8. PubMed ID: 16368379
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Role of pentose phosphate pathway-derived NADPH in hypoxic pulmonary vasoconstriction.
    Gupte SA, Okada T, McMurtry IF, Oka M.
    Pulm Pharmacol Ther; 2006 Jan 01; 19(4):303-9. PubMed ID: 16203165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.